Key takeaways
- Dual agonist: Tirzepatide (Mounjaro, Zepbound) activates both GLP-1 and GIP receptors simultaneously, the first drug in its class to do so
- GLP-1 component reduces appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion
- GIP component works directly on fat tissue, improving insulin sensitivity and reducing visceral fat; the mechanism is not fully understood
- The surprise finding: Tirzepatide and semaglutide suppress appetite by a similar amount, yet tirzepatide produces substantially greater fat loss. GIP's direct effects on fat metabolism appear to explain the difference.
- Weight loss: SURMOUNT-1 trial showed 20.9% mean weight loss at 15 mg over 72 weeks
- Half-life: ~5 days; reaches steady state after ~4 weeks of once-weekly dosing
- FDA approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023)
Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight loss, is the first medication to simultaneously activate two distinct hormone receptors: the GLP-1 receptor and the GIP receptor. That dual-receptor approach is why it produces meaningfully greater weight loss than semaglutide (Ozempic, Wegovy), which targets GLP-1 alone.
But the mechanism is more interesting, and more honest, than the marketing suggests. Researchers have discovered that tirzepatide and semaglutide suppress appetite by a similar amount, yet tirzepatide delivers far greater fat loss. The reason isn't fully settled. What follows covers what is known, what is still under investigation, and why the distinction matters. For a broader overview of what tirzepatide is and its approved uses, see the tirzepatide hub.
(15 mg, 72 weeks)
What makes tirzepatide a dual agonist?
The term dual agonist means tirzepatide binds and activates two different receptors: the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). An agonist is a molecule that binds to a receptor and triggers a biological response, like a key turning a lock.
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones: hormones released by your gut after you eat. They signal to the pancreas, brain, and other tissues that food has arrived. Tirzepatide mimics both at once.
Structurally, tirzepatide is a synthetic 39-amino-acid peptide built on the backbone of native GIP. It carries a C20 fatty diacid chain that locks it tightly to albumin (a blood protein), which slows elimination and gives it its ~5-day half-life, long enough for once-weekly dosing.[2]
Its developer Eli Lilly coined the term "twincretin" to describe this GIP + GLP-1 combination.[3]
Tirzepatide simultaneously activates both the GIP receptor and the GLP-1 receptor — the defining feature of its "twincretin" mechanism.
How the GLP-1 receptor works
The GLP-1 receptor is the same one targeted by semaglutide. It is found in the pancreas, gut, and brain. When tirzepatide activates it, three things happen:
💊 Appetite suppression
GLP-1R activation in the hypothalamus (the brain's appetite control centre) reduces hunger signals and increases the feeling of fullness. It also counteracts ghrelin, the hormone that drives you to eat.
🍽️ Slowed gastric emptying
Food leaves your stomach more slowly. Meals feel more filling and blood sugar rises more gradually after eating. This is also why nausea is the most common side effect. See the side effects guide for management strategies.
🩸 Glucose-dependent insulin release
Pancreatic beta cells release insulin only when blood sugar is elevated. This is critical: it means tirzepatide stimulates insulin when you need it, but stops when blood sugar is normal, so hypoglycaemia (dangerously low blood sugar) is not a risk unless combined with insulin or sulfonylureas.[4]
What the GIP receptor does, and why it's surprising
This is where tirzepatide gets genuinely interesting, and where the science is less settled.
GIP receptors are found in the pancreas, adipose tissue (fat), bone, and brain. Native GIP was originally studied in the context of diabetes, where its role appeared paradoxical: GIP receptor activation can both stimulate and suppress glucagon depending on metabolic conditions. For years, researchers considered GIP a less useful target than GLP-1.[3]
Tirzepatide flipped that assumption. When the GIP receptor is activated alongside GLP-1R, the effects on fat tissue are significant:
- Improved glucose uptake in fat cells, independent of weight loss
- Reduced visceral adipose tissue (VAT): the metabolically harmful fat around your organs
- Direct effects on insulin sensitivity: research estimates only ~20% of tirzepatide's insulin sensitivity gains are explained by weight loss alone, suggesting GIP is acting directly on tissue[9]
- Modulation of lipolysis: how fat cells release stored fat for energy
⚠️ An important caveat: The GIP receptor's exact role in fat loss is still being worked out. Researchers know the effect is real; the clinical trial data is clear. But the precise signalling chain from GIP receptor activation to fat mass reduction in humans is not fully understood. Do not accept sources that present this as settled biology.
Why tirzepatide isn't simply double semaglutide
Adding a second receptor target sounds straightforward, but tirzepatide's design is more nuanced. A 2022 study by Coskun et al. in JCI Insight described tirzepatide as an imbalanced and biased dual agonist: it does not activate both receptors equally or in the same way as native hormones.[2]
Imbalanced affinity
Tirzepatide binds the GIP receptor with affinity matching native GIP, a strong full match. At the GLP-1 receptor, it binds with roughly five times weaker affinity than native GLP-1. This is intentional. A full GLP-1R agonist at high doses risks receptor desensitisation: the receptor becomes less responsive over time. By using a gentler touch at GLP-1R, tirzepatide may maintain more sustained responsiveness.[2]
Biased signalling at the GLP-1 receptor
Receptors can be activated through different internal pathways. At the GLP-1R, tirzepatide strongly favours the cAMP pathway (which drives insulin secretion) over the β-arrestin pathway (which promotes receptor internalisation and shutdown). The practical effect: tirzepatide triggers insulin signalling while causing less GLP-1 receptor shutdown than a full GLP-1 agonist would. This may allow higher effective doses without the ceiling that limits GLP-1 monotherapy.[2]
The bottom line: tirzepatide is engineered to exploit both receptors in a specific, purposeful way, not simply to dump two agonists into one molecule.
How tirzepatide suppresses appetite
Both GLP-1R and GIPR activation contribute to appetite suppression, though GLP-1 carries most of the load for this effect. When tirzepatide activates GLP-1 receptors in the hypothalamus and brainstem, hunger signals decrease. Meals feel more filling. The urge to eat is reduced: not eliminated, but meaningfully diminished.
Gastric emptying slows, which extends the period of satiety after each meal and flattens post-meal blood sugar spikes. Over time, patients eat less at each meal and feel satisfied faster.
GIP receptors in the hypothalamus may also play a role in appetite regulation, though the evidence in humans is less established than for GLP-1. Research in this area is ongoing.[6]
Tirzepatide does not broadly cross the blood-brain barrier. Its CNS effects are mediated through specialised areas of the brain where the blood-brain barrier is permeable (such as the hypothalamus and area postrema), rather than through general brain entry.
Beyond appetite: the fat loss question researchers are still working out
The genuinely surprising finding is one most sources gloss over.
A controlled secondary analysis published in Diabetes Care (Chavda et al., 2023) compared tirzepatide 15 mg, semaglutide 1 mg, and placebo in 117 patients with type 2 diabetes over 28 weeks. The result: tirzepatide and semaglutide reduced appetite and meal-time energy intake by a similar amount. Yet tirzepatide achieved significantly greater reduction in total fat mass.[7]
If appetite suppression is similar, something else must be driving the fat loss difference. Two mechanisms are under active investigation.
GIP's direct effects on adipose tissue
A 2024 review (Gastaldelli et al., PMC 2024) examined what GIP receptor activation does to fat tissue specifically. The findings include:
- Enhanced glucose uptake directly in fat cells
- Preferential reduction of visceral adipose tissue (VAT), the metabolically harmful fat stored around the liver, intestines, and other organs, with reductions of −1.10 to −1.65 litres at 52 weeks[9]
- Improvements in insulin sensitivity that are largely direct GIP effects, not secondary to weight loss (only ~20% of the insulin sensitivity gain is weight-loss-mediated)[9]
These findings suggest tirzepatide's GIP component actively reshapes adipose tissue metabolism in a way semaglutide cannot.
🔬 Brown adipose tissue activation (preclinical finding)
A February 2026 mouse study by Peyrou et al. (Biomedicine & Pharmacotherapy) found that tirzepatide directly activates brown adipose tissue (BAT), the metabolically active fat that burns calories to generate heat, independently of food intake reduction. Mice treated with tirzepatide showed increased caloric burning and production of beneficial signalling proteins called batokines.[8]
⚠️ This is preclinical data only. The BAT finding is from a mouse study. It has not been confirmed in humans. It is consistent with the mechanistic picture, but do not treat it as established clinical evidence.
Taken together, the current evidence points to GIP receptor effects on adipose tissue metabolism, rather than appetite suppression alone, as the likely explanation for tirzepatide's fat loss advantage. The exact pathway remains under investigation.
See How Tirzepatide Builds in Your System
Use our free pharmacokinetic calculator to model drug levels over time, visualise when you'll reach steady state, and plan your titration schedule.
Clinical results: what tirzepatide actually achieves
The mechanism is one thing; what happened in humans is another. The trial data is solid.
SURMOUNT-1: Obesity without type 2 diabetes
The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) enrolled 2,539 adults with obesity but without type 2 diabetes. Participants received weekly injections for 72 weeks. Results at the highest dose (15 mg):[1]
| Dose | Mean Weight Loss | ≥5% Loss | ≥20% Loss |
|---|---|---|---|
| Placebo | −3.1% | 35% | 3% |
| 5 mg | −15.0% | 85% | 30% |
| 10 mg | −19.5% | 89% | 50% |
| 15 mg | −20.9% | 91% | 57% |
SURPASS-2: Head-to-head vs semaglutide in type 2 diabetes
SURPASS-2 (Frías et al., NEJM 2021) compared all three tirzepatide doses against semaglutide 1 mg weekly in 1,879 adults with type 2 diabetes over 40 weeks. All tirzepatide doses outperformed semaglutide on both HbA1c and weight loss:[5]
| Treatment | HbA1c Reduction | Weight Loss (kg) |
|---|---|---|
| Semaglutide 1 mg | −1.86 pp | −5.7 kg |
| Tirzepatide 5 mg | −2.01 pp | −7.6 kg |
| Tirzepatide 10 mg | −2.24 pp | −9.3 kg |
| Tirzepatide 15 mg | −2.30 pp | −11.2 kg |
A large real-world study in JAMA Internal Medicine (Sikirica et al., 2023) confirmed the SURPASS-2 findings extend beyond RCTs. In a propensity-matched cohort of US adults, tirzepatide users achieved 6.9% greater weight loss than semaglutide users at 12 months.[10]
For a detailed comparison of outcomes across the two drugs, see the tirzepatide vs semaglutide comparison.
How tirzepatide controls blood sugar
Tirzepatide controls blood sugar through three complementary mechanisms:
- Glucose-dependent insulin secretion: Both GLP-1R and GIPR activation trigger insulin release from pancreatic beta cells, but only when blood glucose is elevated. This is the safety mechanism that prevents hypoglycaemia.
- Glucagon suppression: GLP-1R activation consistently suppresses glucagon, the hormone that tells your liver to release stored glucose. Less glucagon means less hepatic glucose production and lower fasting blood sugar. The GIP component has a more complex relationship with glucagon (it can both raise and suppress it depending on metabolic context), but the net clinical effect of tirzepatide is glucagon suppression.[3]
- Slowed glucose absorption: Delayed gastric emptying means glucose from meals enters the bloodstream more gradually, flattening post-meal spikes.
In SURPASS-1 (Rosenstock et al., 2021), tirzepatide reduced HbA1c by −1.87% to −2.07% vs placebo over 40 weeks, with up to 52% of participants reaching non-diabetic HbA1c levels below 5.7%.[4]
Tirzepatide stimulates insulin release from pancreatic beta cells only when blood glucose is elevated, reducing both fasting and post-meal blood sugar.
Track Your Tirzepatide Progress
Model drug accumulation, log your doses, and visualise pharmacokinetics with the GLP3 Planner tirzepatide calculator.
How long tirzepatide stays in your system
Tirzepatide's pharmacokinetics explain why it works as a once-weekly injection and why it takes time to feel the full effect.
The ~5-day half-life means it takes approximately four to five half-lives (3–4 weeks) to reach steady-state drug levels at any given dose. This is why tirzepatide's titration protocol spaces dose increases 4 weeks apart: it ensures you experience the full effect of each dose before stepping up.[6]
After a single injection, drug concentration peaks within 8–72 hours, then declines gradually. Because the C20 fatty diacid chain keeps tirzepatide bound tightly to albumin in the blood, very little is excreted before the next dose. Metabolism occurs through proteolytic cleavage, fatty acid beta-oxidation, and amide hydrolysis, the same pathways used for protein digestion. This means no hepatic or renal dose adjustments are needed for mild-to-moderate impairment.[6]
Use the tirzepatide calculator to visualise how drug levels build across your dosing schedule and when you'll reach steady state. For detailed titration protocols, see the tirzepatide dosing guide.
Individual variation: The ~5-day half-life is a population mean. Body composition, renal function, and other factors produce meaningful individual variation. The GLP3 Planner calculator uses this canonical value for modelling, the same figure used across all tirzepatide content on this site.
Frequently asked questions
How does tirzepatide work for weight loss?
Tirzepatide produces weight loss primarily through appetite suppression (via GLP-1 and GIP receptor activation in the brain), slower gastric emptying (food leaves the stomach more slowly, prolonging fullness), and direct effects on fat tissue through the GIP receptor. Research shows tirzepatide and semaglutide suppress appetite by a similar amount, yet tirzepatide achieves significantly greater fat mass reduction. The GIP component appears to contribute to fat loss through metabolic mechanisms beyond appetite alone. SURMOUNT-1 showed mean weight loss of 20.9% at 15 mg over 72 weeks in adults with obesity but without type 2 diabetes.
What is a dual GIP and GLP-1 receptor agonist?
A dual GIP and GLP-1 receptor agonist is a drug that binds and activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) simultaneously. GLP-1 and GIP are both incretin hormones released by the gut after eating. Each receptor triggers different biological effects: GLP-1R drives appetite suppression and insulin secretion; GIPR affects insulin sensitivity, fat tissue metabolism, and glucose uptake. Tirzepatide is the first approved dual GIP/GLP-1 receptor agonist, also called a "twincretin."
What makes tirzepatide different from semaglutide?
Semaglutide (Ozempic, Wegovy) targets only the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) also activates the GIP receptor. Clinically, this produces greater weight loss: tirzepatide achieved 6.9% more weight loss than semaglutide at 12 months in a large real-world study, and 5.5 kg more weight loss in the SURPASS-2 head-to-head trial. The mechanism of this superiority is not fully explained by appetite suppression alone, pointing to GIP's direct effects on fat tissue metabolism as a key differentiator. For a full comparison, see the tirzepatide vs semaglutide guide.
Does tirzepatide suppress appetite or boost metabolism?
Both, likely. The primary mechanism is appetite suppression through GLP-1 and GIP receptor activation in the brain. But research (Chavda et al., 2023) found tirzepatide and semaglutide produce similar appetite and energy intake reductions, yet tirzepatide achieves significantly greater fat mass loss. This suggests tirzepatide also affects fat metabolism directly, probably through GIP receptor activity in adipose tissue. A 2026 mouse study found tirzepatide activates brown adipose tissue (which burns calories) independently of food intake reduction, but this has not yet been confirmed in humans.
How does tirzepatide lower blood sugar?
Tirzepatide lowers blood sugar through three mechanisms: (1) it stimulates insulin secretion from the pancreas in a glucose-dependent way (only when blood sugar is elevated, so it does not cause hypoglycaemia); (2) it suppresses glucagon, reducing the liver's release of stored glucose; and (3) it slows gastric emptying, flattening the post-meal glucose spike. In SURPASS-1, tirzepatide reduced HbA1c by up to 2.07 percentage points vs placebo, with 52% of participants reaching non-diabetic HbA1c levels below 5.7%.
How long does tirzepatide take to work?
Appetite suppression begins within the first few days. Meaningful weight loss typically becomes visible after 4–8 weeks. Because tirzepatide has a ~5-day half-life, it takes ~4 weeks to reach steady-state drug levels at each dose, which is why dose increases are spaced at least 4 weeks apart. Full therapeutic effect at the maximum dose takes months to accumulate. In SURMOUNT-1, significant weight loss was measured at 72 weeks. The tirzepatide calculator can model how drug levels build across your schedule.
Does tirzepatide cause nausea, and why?
Yes, nausea is the most common side effect, primarily caused by the GLP-1 component slowing gastric emptying. When food exits the stomach slowly and you eat a large or fatty meal, the backed-up digestive tract can trigger nausea. It is usually worst in the first 1–2 weeks at a new dose and improves as the body adapts, even though drug levels remain constant. Slow dose titration, smaller meals, and avoiding high-fat foods help significantly. For detailed management strategies, see the tirzepatide side effects guide.
Is tirzepatide FDA-approved?
Yes. Tirzepatide is FDA-approved under two brand names: Mounjaro (approved May 2022 for type 2 diabetes management) and Zepbound (approved November 2023 for chronic weight management in adults with obesity or overweight with a weight-related condition). In December 2024, Zepbound also received FDA approval for obstructive sleep apnea, the first drug approved for this indication. Tirzepatide is not approved for type 1 diabetes. Compounded versions are available through licensed compounding pharmacies, though these differ from the FDA-approved pharmaceutical product. If using compounded tirzepatide, see our tirzepatide reconstitution guide for step-by-step mixing instructions and concentration charts.
Plan Your Tirzepatide Journey
Model dosing schedules, prepare vials precisely, and get personalised answers — all free.
The bottom line
Tirzepatide works by activating two incretin hormone receptors, GLP-1 and GIP, simultaneously rather than one at a time. The GLP-1 component drives appetite suppression, slower gastric emptying, and insulin secretion. The GIP component adds direct effects on fat tissue: improved glucose uptake, preferential reduction of visceral fat, and insulin sensitivity gains that go beyond what weight loss alone would explain.
The key finding that distinguishes tirzepatide from semaglutide is not that it suppresses appetite more; it doesn't, at least not by much. What it does differently is produce substantially greater fat loss through mechanisms that are still being characterised. The GIP receptor's role in adipose tissue metabolism appears central to this effect.
The clinical data is clear: 20.9% mean weight loss at 72 weeks in SURMOUNT-1, clear superiority over semaglutide in head-to-head trials, and real-world confirmation from large observational data. The pharmacokinetics (~5-day half-life, ~4-week steady state, once-weekly dosing) are designed for sustained, stable drug exposure. For the full picture on how to use tirzepatide safely and effectively, the dosing guide and microdosing guide cover practical protocols in detail.
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. DOI: 10.1056/NEJMoa2206038. [PubMed]
- Coskun T, Sloop KW, Loghin C, et al. Tirzepatide Is an Imbalanced and Biased Dual GIP and GLP-1 Receptor Agonist. JCI Insight. 2022;7(12):e156697. DOI: 10.1172/jci.insight.156697. [JCI Insight]
- Nauck MA, Quast DR, Wefers J, Meier JJ. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021;12(1):143–157. DOI: 10.1007/s13300-020-00981-0. [PMC]
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021;44(12):2819–2831. DOI: 10.2337/dc21-1901. [PubMed]
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515. DOI: 10.1056/NEJMoa2107519. [PubMed]
- Tirzepatide. In: StatPearls. NCBI Bookshelf. Updated 2024. [NCBI]
- Chavda VP, Ajabiya J, Teli D, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023;46(5):998–1004. [PMC]
- Peyrou M, et al. Tirzepatide Activates Brown Adipose Tissue Beyond Weight Loss. Biomedicine & Pharmacotherapy. 2026;119057. DOI: 10.1016/j.biopha.2026.119057. [MedicalXpress]
- Gastaldelli A, et al. Tirzepatide in Adipose Tissue and Metabolism: A 2024 Review. PMC. 2024. [PMC]
- Sikirica MV, et al. Comparative Effectiveness of Tirzepatide vs Semaglutide for Weight Loss in US Adults. JAMA Internal Medicine. 2023. [JAMA]
Medical disclaimer
Nothing here constitutes medical advice or substitutes for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results vary. Tirzepatide carries a boxed warning regarding potential thyroid C-cell tumour risk (a class effect shared with GLP-1 receptor agonists). It is not approved for use in type 1 diabetes. Report any concerning symptoms to your healthcare provider promptly.
Related tirzepatide articles
Tirzepatide hub
Complete resource centre: approvals, dosing, safety, and tools.
Dosing guide
Full titration protocol, starting doses, and conservative schedules.
Side effects
What to expect and how to manage GI and other adverse effects.
Tirzepatide vs semaglutide
Head-to-head comparison: mechanism, efficacy, and cost.
Microdosing tirzepatide
Split-dose protocols for improved tolerability at lower costs.
Retatrutide vs tirzepatide
Triple agonist vs dual agonist: the mechanism and results compared.
Tirzepatide reconstitution guide
How to mix compounded tirzepatide with BAC water, with concentration charts and calculator.